Gidroxlorotiazid
When ATH:
C03AA03
Characteristic.
White or yellow-brown crystalline powder. It is soluble in water, it is soluble in methanol, insoluble in ether, easily soluble in alkaline solutions. Molecular weight 297,72.
Pharmacological action.
Diuretic, gipotenzivnoe.
Application.
Arterial hypertension, congestive heart failure, glaucoma, nesaharnыy diabetes, liver cirrhosis with portal hypertension and edema-ascites syndrome, jade, nephrosis; rarely - toxemia of pregnancy.
Contraindications.
Hypersensitivity, diabetes, gout, lactation.
Restrictions apply.
Severe cerebral or coronary atherosclerosis, expressed human liver, kidney, pregnancy.
Side effects.
Kaliopenia, hypochloraemic alkalosis, nausea, vomiting, loss of appetite, diarrhea or constipation, thirst, dizziness, headache, weakness, paraesthesia, orthostatic hypotension, tachycardia, cholestasis, pancreatitis, gemoliz, gipoplasticheskaya anemia, agranulocytosis, allergic reactions.
Cooperation.
Enhances the toxicity of cardiac glycosides, non-depolarizing muscle relaxants. Reduces the effect of oral contraceptives. Reduce the excretion of lithium salts.
Overdose.
Dry mouth, weakness, drowsiness, tachycardia, gipotenziya, oligurija.
Dosing and Administration.
Inside, with hypertension - 25-100 mg 1 once a day, in heart failure and cirrhosis - up 200 mg / day. For children a daily dose - 2 mg / kg, the maximum dose at the age of 6 Months - 3,5 mg / kg / day, to 2 years - 12,5-37,5 mg / day, 3-12 years - 100 mg / day.
Precautions.
During prolonged therapy monitoring the concentration of electrolytes in the blood plasma.
Cooperation
| Active substance | Description of interaction |
| Akarʙoza | FMR: antagonizm. Against the background of the effect of hydrochlorothiazide is attenuated; with a joint appointment is necessary to monitor the concentration of glucose in the blood. |
| Allopurinol | FMR. Against the background of hydrochlorothiazide increases the risk of toxicity. |
| Alfuzozin | FMR: synergism. Strengthens (mutually) hypotensive effect. |
| Amantadin | Against the background of possible reduction in clearance of hydrochlorothiazide, increase in plasma concentrations and an increased risk of toxic effects. |
| Amiodarone | Against the background of hydrochlorothiazide may increase the risk of arrhythmias, due to hypokalemia. |
| Amlodipine | FMR: synergism. Strengthens (mutually) hypotensive effect. |
| Atenolol | FMR: synergism. Strengthens (mutually) antihypertensive effect. |
| Atrakuriya besilate | FMR: synergism. Against the background of hydrochlorothiazide accelerated and enhanced muscle relaxation. |
| Betaksolol | FMR: synergism. Strengthens (mutually) hypotensive effect. |
| Betametazon | FMR: synergism. Against the backdrop of intensified hydrochlorothiazide loss of electrolytes, especially potassium, and increased risk of hypokalemia. |
| Bisoprolol | FMR: synergism. Strengthens (mutually) hypotensive effect. |
| Buprenorphine | FMR. It increases the likelihood of orthostatic hypotension. |
| Valsartan | FMR: synergism. Strengthens (mutually) antihypertensive effect. |
| Warfarin | FMR: synergism. Against the background of enhanced effect of hydrochlorothiazide. |
| Vekuroniya bromide | FMR: synergism. Against the background of hydrochlorothiazide accelerated and enhanced muscle relaxation. |
| Verapamil | FMR: synergism. Strengthens (mutually) antihypertensive effect. |
| Gidrokortizon | FMR: synergism. Against the backdrop of intensified hydrochlorothiazide loss of electrolytes, especially potassium, and increased risk of hypokalemia. |
| Glimepiride | FMR: antagonizm. Against the background of hydrochlorothiazide (can cause hyperglycemia) attenuated effect; the combined appointment may need to increase the dose. |
| Glipizide | FMR: antagonizm. Against the background of the effect of hydrochlorothiazide is attenuated; with a joint appointment is necessary to monitor the concentration of glucose in the blood. |
| Dexamethasone | FMR: synergism. Against the backdrop of intensified hydrochlorothiazide loss of electrolytes, especially potassium, and increased risk of hypokalemia. |
| Digoxin | FMR. Against the background of hydrochlorothiazide, increases the loss of potassium, increased risk of toxicity. |
| Diclofenac | FMR: antagonizm. Reduces the diuretic, natriuretic and hypotensive effects. |
| Diclofenac potassium | FMR: antagonizm. Reduces the diuretic, natriuretic and hypotensive effects. |
| Diltiazem | FMR: synergism. Strengthens (mutually) antihypertensive effect. |
| Doksazozin | FMR: synergism. Strengthens (mutually) hypotensive effect. |
| Ibuprofen | FMR: antagonizm. Reduces the diuretic, natriuretic and hypotensive effects. |
| Indapamid | FMR: synergism. Strengthens (mutually) effects. |
| Indomethacin | FMR: antagonizm. Reduces the diuretic, natriuretic and antihypertensive effects. |
| Insulin aspart | FMR: antagonizm. Against the background of the effect of hydrochlorothiazide is attenuated; the combined appointment may need to increase the dose. |
| Insulin glargine | FMR: antagonizm. Against the background of hydrochlorothiazide (can cause hyperglycemia) attenuated effect; the combined appointment may need to increase the dose. |
| Insulin dvuhfaznыy [human genetic engineering] | FMR: antagonizm. Against the background of hydrochlorothiazide (can cause hyperglycemia) attenuated effect; the combined appointment may need to increase the dose. |
| Insulin lispro | FMR: antagonizm. Against the background of hydrochlorothiazide (can cause hyperglycemia) attenuated effect; the combined appointment may need to increase the dose. |
| Insulin soluble [pork monocomponent] | FMR: antagonizm. Against the background of hydrochlorothiazide (can cause hyperglycemia) attenuated effect; the combined appointment may need to increase the dose. |
| Irbesartan | FMR: synergism. Strengthens (mutually) hypotensive effect. |
| Candesartan cïleksetïl | FMR: synergism. Strengthens (mutually) antihypertensive effect. |
| Captopril | FMR: synergism. Strengthens (mutually) hypotensive effect. |
| Klonidin | FMR: synergism. Strengthens (mutually) antihypertensive effect. |
| Codeine | FMR: synergism. It increases the risk of orthostatic hypotension. |
| Kortizon | FMR: synergism. Against the backdrop of intensified hydrochlorothiazide loss of electrolytes, especially potassium, and increased risk of hypokalemia. |
| Levothyroxine sodium | FMR. On the background you can change the effect of hydrochlorothiazide; joint application requires caution. |
| Lisinopril | FMR: synergism. Strengthens (mutually) hypotensive effect. |
| Lithium carbonate | FKV. FMR. Against the background of hydrochlorothiazide reduced clearance and an increased risk of toxic effects. |
| Lozartan | FMR: synergism. Strengthens (mutually) antihypertensive effect. |
| Meloxicam | FMR: antagonizm. Reduces the diuretic, natriuretic and hypotensive effects. |
| Methyldopa | FMR: synergism. Strengthens (mutually) hypotensive effect. |
| Methylprednisolone | FMR: synergism. Against the backdrop of intensified hydrochlorothiazide loss of electrolytes, especially potassium, and increased risk of hypokalemia. |
| Methoxsalen | FMR. Against the background of the effect of hydrochlorothiazide may be increased. |
| Metoprolol | FMR: synergism. Strengthens (mutually) hypotensive effect. |
| Metformin | FMR: antagonizm. Against the background of the effect of hydrochlorothiazide is attenuated; the combined appointment may require an increased dose. |
| Morphine sulfate | FMR: synergism. It increases the risk of orthostatic hypotension. |
| Moexipril | FMR: synergism. Strengthens (mutually) hypotensive effect. |
| Nadolol | FMR: synergism. Strengthens (mutually) antihypertensive effect. |
| Nitroglycerin | FMR: synergism. Enhances the hypotensive effect. |
| Nifedipine | FMR: synergism. Strengthens (mutually) hypotensive effect. |
| Norepinephrine | FMR: antagonizm. Against the background of the effect of hydrochlorothiazide is reduced. |
| Perindopril | FMR: synergism. Strengthens (mutually) antihypertensive effect. |
| Pindolol | FMR: synergism. Strengthens (mutually) hypotensive effect. |
| Pioglitazone | FMR: antagonizm. Against the background of hydrochlorothiazide (can cause hyperglycemia) attenuated effect; the combined appointment may require a higher dose. |
| Piroxicam | FMR: antagonizm. Reduces the diuretic, natriuretic and hypotensive effects. |
| Prazosin | FMR: synergism. Strengthens (mutually) antihypertensive effect. |
| Prednisolone | FMR: synergism. Against the backdrop of intensified hydrochlorothiazide loss of electrolytes, especially potassium, and increased risk of hypokalemia. |
| Propranolol | FMR: synergism. Strengthens (mutually) antihypertensive effect. |
| Ramipril | FMR: synergism. Strengthens (mutually) antihypertensive effect. |
| Repaglinide | FMR: antagonizm. Against the background of the effect of hydrochlorothiazide is attenuated; the combined appointment may require higher doses. |
| Risperidone | FMR: synergism. Increases (mutually) the risk of orthostatic hypotension. |
| Rokuroniya bromide | FMR: synergism. Against the background of hydrochlorothiazide accelerated and enhanced muscle relaxation. |
| Rosiglitazone | FMR: antagonizm. Against the background of hydrochlorothiazide (can cause hyperglycemia) attenuated effect; the combined appointment may require a higher dose. |
| Salmeterol | FMR. Against the background of hydrochlorothiazide is aggravated hypokalemia. |
| Sotalol | FMR: synergism. Strengthens (mutually) hypotensive effect. |
| Spirapril | FMR: synergism. Strengthens (mutually) antihypertensive effect. |
| Telmisartan | FMR: synergism. Strengthens (mutually) hypotensive effect. |
| Terazosin | FMR: synergism. Strengthens (mutually) hypotensive effect. |
| Timolol | FMR: synergism. Strengthens (mutually) hypotensive effect. |
| Trandolapril | FMR: synergism. Strengthens (mutually) antihypertensive effect. |
| Triamcinolone | FMR: synergism. Against the backdrop of intensified hydrochlorothiazide loss of electrolytes, especially potassium, and increased risk of hypokalemia. |
| Felodipine | FMR: synergism. Strengthens (mutually) antihypertensive effect. |
| Phenylbutazone | FMR: antagonizm. Reduces the diuretic, natriuretic and antihypertensive effects. |
| Phenobarbital | FMR: synergism. It increases the chance of orthostatic hypotension. |
| Fentanyl | FMR: synergism. It increases the risk of orthostatic hypotension. |
| Fludrokortizon | FMR: synergism. Intensifies (mutually) electrolyte spillage, especially potassium, It increases the risk of hypokalemia. |
| Fluconazole | FKV. Against the background of hydrochlorothiazide due to lower clearance (a third) in 1,5 fold increase in AUC and Cmax. |
| Fosinopril | FMR: synergism. Strengthens (mutually) effect. |
| Furosemid | FMR: synergism. Strengthens (mutually) effects. |
| Quinidine | FKV. Against the background of reduced excretion of hydrochlorothiazide. |
| Xlortalidon | FMR: synergism. Strengthens (mutually) effects. |
| Celecoxib | FMR: antagonizm. Reduces the diuretic, natriuretic and antihypertensive effects. |
| Enalapril | FMR: synergism. Strengthens (mutually) hypotensive effect. |
| Enalaprilat | FMR: synergism. Strengthens (mutually) antihypertensive effect. |
| Epinephrine | Against the background of the effect of hydrochlorothiazide is attenuated. |
| Eprosartan | FMR: synergism. Strengthens (mutually) hypotensive effect. |
| Esmolol | FMR: synergism. Strengthens (mutually) hypotensive effect. |
| Ethanol | FMR: synergism. It increases the chance of orthostatic hypotension. |
